SYRE Q4 2022 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$168,000-95.4% YoY

Gross Profit

-$322,000-191.7% margin

Operating Income

-$19M-11406.0% margin

Net Income

-$19M-11203.6% margin

EPS (Diluted)

$-7.20

QoQ Revenue Growth

-3.4%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$71M

Total Liabilities

$21M

Stockholders' Equity

$50M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$168,000	$4M	-95.4%
Gross Profit	-$322,000	$3M	-110.2%
Operating Income	-$19M	-$20M	+6.3%
Net Income	-$19M	-$20M	+7.9%